611225-86-6

Basic information

• Product Name: 4-(4-ETHYL-PIPERAZIN-1-YLMETHYL)-PHENYLAMINE
• Synonyms: 4-(4-ETHYL-PIPERAZIN-1-YLMETHYL)-PHENYLAMINE;Benzenamine, 4-[(4-ethyl-1-piperazinyl)methyl]- (9CI);4-(4-ETHYLPIPERAZIN-1-YLMETHYL)PHENYLAMINE, 95+%;Albb-007371;4-((4-ethylpiperazin-1-yl)methyl)benzenamine;4-(4-Ethylpiperazin-1-ylmethyl)
• CAS NO: 611225-86-6
• Molecular Formula: C₁₃H₂₁N₃
• Molecular Weight: 219.33
• EINECS: 604-604-1
• Product Categories: ETHYL
• Mol File: 611225-86-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 346.2 °C at 760 mmHg
• Flash Point: 160.8 °C
• Appearance: /
• Density: 1.06 g/cm³
• Vapor Pressure: 5.84E-05mmHg at 25°C
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 7.85±0.10(Predicted)
• CAS DataBase Reference: 4-(4-ETHYL-PIPERAZIN-1-YLMETHYL)-PHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-ETHYL-PIPERAZIN-1-YLMETHYL)-PHENYLAMINE(611225-86-6)
• EPA Substance Registry System: 4-(4-ETHYL-PIPERAZIN-1-YLMETHYL)-PHENYLAMINE(611225-86-6)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 611225-86-6(Hazardous Substances Data)

Usage

General Description

4-(4-ethyl-piperazin-1-ylmethyl)-phenylamine is a chemical compound with the molecular formula C15H24N2. It is a derivative of phenylamine with a piperazine ring and an ethyl group attached to it. 4-(4-ETHYL-PIPERAZIN-1-YLMETHYL)-PHENYLAMINE has potential pharmacological and therapeutic applications, with some research suggesting its use as a possible drug candidate for the treatment of certain medical conditions. Its precise properties and potential uses are a subject of ongoing study and research in the field of medicinal chemistry and pharmacology.

InChI:InChI=1/C13H21N3/c1-2-15-7-9-16(10-8-15)11-12-3-5-13(14)6-4-12/h3-6H,2,7-11,14H2,1H3/p+2

Upstream product

• 414880-35-6 1-ethyl-4-(4-nitrobenzyl)piperazine 

Downstream Products

• 853297-55-9 N-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-N'-[4-(4-ethylpiperazin-1-ylmethyl)-phenyl]-urea 
• 1350545-53-7 4-cyclopentylamino-2-(4-((4-ethylpiperazin-1-yl)methyl)phenylamino)-5-nitropyrimidine 
• 882405-19-8 5-(6-chloro-pyrimidin-4-yloxy)-2,3-dihydro-indole-1-carboxylic acid [4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-amide 
• 611225-87-7 4-[(4-ethylpiperazin-1-yl)methyl]benzeneisothiocyanate 

Relevant articles and documents

NOVEL INHIBITORS OF MAP4K1

The invention relates to novel inhibitors of MAP4K1 (HPK1) useful for the treatment of diseases or disorders characterised by dysregulation of the signal transduction pathways associated with MAPK activation, including hyperproliferative diseases, diseases of immune system dysfunction, inflammatory disorders, neurological diseases, and cardiovascular diseases. The invention further relates to pharmaceutical compositions comprising the same and methods of treatment of said diseases and disorders. The inhibitors are of formula (I) wherein the definitions for A, D, E, F, R5, R6, R7, Z, ring Q, n, x and y are as given in the application.

PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS

The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.

Substituted benzazoles and methods of their use as inhibitors of Raf kinase

New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.